SHANDONG PHARM GLASS increases its risk exposure and slightly lowers to Neutral
SHANDONG PHARM GLASS (CN), a company active in the Medical Equipment industry, now shows a lower overall rating. The independent financial analyst theScreener confirms the fundamental rating of 3 out of 4 stars. However, the market behaviour deterioration triggered a risk requalification, which can be thus described as moderately risky. theScreener believes that increased risk justifies the general evaluation downgrade to Neutral. As of the analysis date December 21, 2021, the closing price was CNY 40.32 and its expected value was estimated at CNY 39.52.Shandong Pharmaceutical Glass is engaged in the production and sale of molded antibiotics bottles, glass tubes, retort pliable ampoules, tube oral liquid bottles, tube antibiotics bottles, glass medicine bottles, glass transfusion bottles, medical-use plastic bottles, medical-use butyl rubber bottle cork, aluminum and plastic combination cover, and medical equipment and machinery; the processing and sale of paper boxes; sand-cast molding; provision of automobile freight transportation; import and export businesses; retail of oil product; and production of oxygen. Through its subsidiaries, Co. is also engaged in the construction and installation of buildings and structures.
Empowering Investors
theScreener is the market leader for independent valuations of financial securities, equities, sectors and markets, and new funds. theScreener's ratings, analyses are used by leading banks, asset managers and financial portals. Approximately 10,000 workstations benefit from theScreener's services, with over millions of customer accounts actively analysed.
- Worldwide coverage: theScreener analyses cover around 6'500 Stocks, i.e 95% of the world Market Capitalization. theScreener state of art: We provide
- theScreener state of art: We provide easy to use and complete analyses over Stocks, including Fundamentals / Technical / Risk/ Peer / Alternatives analyses.
- For Research Pool community, we provide twice a week around 500 new equity analyses. We produce analyses about equities which have been upgraded or downgraded.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.